Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: A meta-analysis and systematic review

Oncotarget

Volumn 8, Issue 28, 2017, Pages 46461-46467

  Wang, Jie ^a   Shen, Yigen ^a   Wang, Jiaoni ^a   Xue, Yangjing ^a   Liao, Lianming ^b   Thapa, Saroj ^a   Ji, Kangting ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Basal cell carcinoma; Malignant melanoma; Meta analysis; Phosphodiesterase type 5 inhibitors; Systematic review

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CANCER RISK; DISEASE ASSOCIATION; DRUG EXPOSURE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; MELANOMA; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; CASE CONTROL STUDY; PATHOLOGY; RISK;

CASE-CONTROL STUDIES; HUMANS; MELANOMA; PHOSPHODIESTERASE 5 INHIBITORS; RISK;

EID: 85022196329     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17518     Document Type: Article

References (18)

1. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007; 120:151-7. doi: 10.1016/j.amjmed.2006.06.010
2. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013; 381:153-65. doi: 10.1016/s0140-6736(12)60520-0
3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84:50-6
4. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011; 19:45-57. doi: 10.1016/j. ccr.2010.10.029
5. Dhayade S, Kaesler S, Sinnberg T, Dobrowinski H, Peters S, Naumann U, Liu H, Hunger RE, Thunemann M, Biedermann T, Schittek B, Simon HU, Feil S, et al. Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth. Cell Rep. 2016; 14:2599-610. doi: 10.1016/j.celrep.2016.02.028
6. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445:851-7 doi: 10.1038/nature05661
7. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014; 174:964-70. doi: 10.1001/jamainternmed.2014.594
8. Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L. Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. 2016; 70:808-815. doi: 10.1016/j. eururo.2016.04.035
9. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015; 313:2449-55. doi: 10.1001/jama.2015.6604
10. Matthews A, Langan SM, Douglas IJ, Smeeth L, Bhaskaran K. Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK Clinical Practice Research Datalink. PLoS Med. 2016; 13:e1002037. doi: 10.1371/journal. pmed.1002037
11. Pottegard A, Schmidt SA, Olesen AB, Achacoso N, Van Den Eeden SK, Hallas J, Sorensen HT, Friis S, Habel LA. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer. 2016; 115:895-900. doi: 10.1038/bjc.2016.248
12. Schonrath K, Pan W, Klein-Szanto AJ, Braunewell KH. Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. Mol Carcinog. 2011; 50:319-33. doi: 10.1002/mc.20707
13. Kadam PD, Chuan HH. Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. Int Urogynecol J. 2016; 27:505. doi: 10.1007/s00192-016-2952-5
14. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014; 6:359-68. doi: 10.2147/CLEP.S66677
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603-5. doi: 10.1007/s10654-010-9491-z
16. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015; 132:1795-804. doi: 10.1161/CIRCULATIONAHA.115.017926
17. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280:1690-1
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-60. doi: 10.1136/bmj.327.7414.557